681 related articles for article (PubMed ID: 19625914)
21. Reversals of blood-brain barrier disruption by catalase: a serial magnetic resonance imaging study of experimental optic neuritis.
Guy J; McGorray S; Fitzsimmons J; Beck B; Mancuso A; Rao NA; Hamed L
Invest Ophthalmol Vis Sci; 1994 Aug; 35(9):3456-65. PubMed ID: 8056521
[TBL] [Abstract][Full Text] [Related]
22. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
Tsuda N; Okada M; Murakami T
Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
[TBL] [Abstract][Full Text] [Related]
23. Intercellular imaging by a polyarginine derived cell penetrating peptide labeled magnetic resonance contrast agent, diethylenetriamine pentaacetic acid gadolinium.
Guo YM; Liu M; Yang JL; Guo XJ; Wang SC; Duan XY; Wang P
Chin Med J (Engl); 2007 Jan; 120(1):50-5. PubMed ID: 17254488
[TBL] [Abstract][Full Text] [Related]
24. Blood-brain barrier permeability in rats is altered by exposure to magnetic fields associated with magnetic resonance imaging at 1.5 T.
Prato FS; Wills JM; Roger J; Frappier H; Drost DJ; Lee TY; Shivers RR; Zabel P
Microsc Res Tech; 1994 Apr; 27(6):528-34. PubMed ID: 8012055
[TBL] [Abstract][Full Text] [Related]
25. Assessment of kainate toxicity using contrast enhanced magnetic resonance imaging.
Beravs K; Frangez R; Demsar F
Pflugers Arch; 2000; 440(5 Suppl):R153-4. PubMed ID: 11005651
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI.
Hirschberg H; Wu GN; Madsen SJ
Minim Invasive Neurosurg; 2007 Dec; 50(6):318-23. PubMed ID: 18210352
[TBL] [Abstract][Full Text] [Related]
27. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging.
Starr JM; Wardlaw J; Ferguson K; MacLullich A; Deary IJ; Marshall I
J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):70-6. PubMed ID: 12486269
[TBL] [Abstract][Full Text] [Related]
28. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
Lahrech H; Perles-Barbacaru AT; Aous S; Le Bas JF; Debouzy JC; Gadelle A; Fries PH
J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
[TBL] [Abstract][Full Text] [Related]
29. Contrast enhanced MRI. Evaluation of a canine model of osmotic blood-brain barrier disruption.
Runge VM; Price AC; Wehr CJ; Atkinson JB; Tweedle MF
Invest Radiol; 1985 Nov; 20(8):830-44. PubMed ID: 4077437
[TBL] [Abstract][Full Text] [Related]
30. Quantitative evaluation of the effect of propylene glycol on BBB permeability.
Sood R; Taheri S; Estrada EY; Rosenberg GA
J Magn Reson Imaging; 2007 Jan; 25(1):39-47. PubMed ID: 17173307
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of renal function in normal and hydronephrotic kidneys in rats using gadolinium diethylenetetramine-pentaacetic acid enhanced dynamic magnetic resonance imaging.
Wen JG; Chen Y; Ringgaard S; Frøkiaer J; Jørgensen TM; Stødkilde-Jørgensen H; Djurhuus JC
J Urol; 2000 Apr; 163(4):1264-70. PubMed ID: 10737526
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model.
Runge VM; Biswas J; Wintersperger BJ; Baumann SS; Jackson CB; Herborn CU; Patel T
Invest Radiol; 2006 Mar; 41(3):244-8. PubMed ID: 16481906
[TBL] [Abstract][Full Text] [Related]
33. Early blood-brain barrier disruption in human focal brain ischemia.
Latour LL; Kang DW; Ezzeddine MA; Chalela JA; Warach S
Ann Neurol; 2004 Oct; 56(4):468-77. PubMed ID: 15389899
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Gd-DTPA-induced signal enhancements in rat brain C6 glioma among different pulse sequences in 3-Tesla magnetic resonance imaging.
Sato H; Enmi J; Teramoto N; Hayashi T; Yamamoto A; Tsuji T; Naito H; Iida H
Acta Radiol; 2008 Mar; 49(2):172-9. PubMed ID: 18300142
[TBL] [Abstract][Full Text] [Related]
35. MR molecular imaging of early endothelial activation in focal ischemia.
Barber PA; Foniok T; Kirk D; Buchan AM; Laurent S; Boutry S; Muller RN; Hoyte L; Tomanek B; Tuor UI
Ann Neurol; 2004 Jul; 56(1):116-20. PubMed ID: 15236408
[TBL] [Abstract][Full Text] [Related]
36. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI.
Lüdemann L; Grieger W; Wurm R; Wust P; Zimmer C
Magn Reson Imaging; 2005 Oct; 23(8):833-41. PubMed ID: 16275421
[TBL] [Abstract][Full Text] [Related]
37. Characterization of BBB permeability in a preclinical model of cryptococcal meningoencephalitis using magnetic resonance imaging.
Pai MP; Sakoglu U; Peterson SL; Lyons CR; Sood R
J Cereb Blood Flow Metab; 2009 Mar; 29(3):545-53. PubMed ID: 19066614
[TBL] [Abstract][Full Text] [Related]
38. Rat model of reperfused partial liver infarction: characterization with multiparametric magnetic resonance imaging, microangiography, and histomorphology.
Wu X; Wang H; Chen F; Jin L; Li J; Feng Y; DeKeyzer F; Yu J; Marchal G; Ni Y
Acta Radiol; 2009 Apr; 50(3):276-87. PubMed ID: 19160078
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal assessment of blood-brain barrier leakage during epileptogenesis in rats. A quantitative MRI study.
van Vliet EA; Otte WM; Gorter JA; Dijkhuizen RM; Wadman WJ
Neurobiol Dis; 2014 Mar; 63():74-84. PubMed ID: 24321435
[TBL] [Abstract][Full Text] [Related]
40. Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis.
Nakamura M; Yamashita T; Ueda M; Obayashi K; Sato T; Ikeda T; Washimi Y; Hirai T; Kuwahara Y; Yamamoto MT; Uchino M; Ando Y
Neurology; 2005 Oct; 65(7):1051-6. PubMed ID: 16217058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
